JP2023093656A5 - - Google Patents

Info

Publication number
JP2023093656A5
JP2023093656A5 JP2023070426A JP2023070426A JP2023093656A5 JP 2023093656 A5 JP2023093656 A5 JP 2023093656A5 JP 2023070426 A JP2023070426 A JP 2023070426A JP 2023070426 A JP2023070426 A JP 2023070426A JP 2023093656 A5 JP2023093656 A5 JP 2023093656A5
Authority
JP
Japan
Prior art keywords
invention described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023070426A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023093656A (ja
Filing date
Publication date
Priority claimed from JP2021085852A external-priority patent/JP2021130676A/ja
Application filed filed Critical
Publication of JP2023093656A publication Critical patent/JP2023093656A/ja
Publication of JP2023093656A5 publication Critical patent/JP2023093656A5/ja
Pending legal-status Critical Current

Links

JP2023070426A 2015-08-11 2023-04-21 抗体 Pending JP2023093656A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015159240 2015-08-11
JP2015159240 2015-08-11
JP2021085852A JP2021130676A (ja) 2015-08-11 2021-05-21 抗体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021085852A Division JP2021130676A (ja) 2015-08-11 2021-05-21 抗体

Publications (2)

Publication Number Publication Date
JP2023093656A JP2023093656A (ja) 2023-07-04
JP2023093656A5 true JP2023093656A5 (cg-RX-API-DMAC7.html) 2025-09-09

Family

ID=57983824

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017534378A Active JP6548052B2 (ja) 2015-08-11 2016-08-02 抗体
JP2019101116A Withdrawn JP2019201641A (ja) 2015-08-11 2019-05-30 抗体
JP2021085852A Pending JP2021130676A (ja) 2015-08-11 2021-05-21 抗体
JP2023070426A Pending JP2023093656A (ja) 2015-08-11 2023-04-21 抗体

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2017534378A Active JP6548052B2 (ja) 2015-08-11 2016-08-02 抗体
JP2019101116A Withdrawn JP2019201641A (ja) 2015-08-11 2019-05-30 抗体
JP2021085852A Pending JP2021130676A (ja) 2015-08-11 2021-05-21 抗体

Country Status (13)

Country Link
US (5) US10654931B2 (cg-RX-API-DMAC7.html)
EP (1) EP3336184A4 (cg-RX-API-DMAC7.html)
JP (4) JP6548052B2 (cg-RX-API-DMAC7.html)
KR (2) KR20240149974A (cg-RX-API-DMAC7.html)
CN (2) CN113893341B (cg-RX-API-DMAC7.html)
AU (3) AU2016306320B2 (cg-RX-API-DMAC7.html)
CA (1) CA2995046A1 (cg-RX-API-DMAC7.html)
HK (1) HK1249549A1 (cg-RX-API-DMAC7.html)
IL (2) IL257368B2 (cg-RX-API-DMAC7.html)
MX (2) MX2018001668A (cg-RX-API-DMAC7.html)
PH (1) PH12018500258B1 (cg-RX-API-DMAC7.html)
SG (2) SG10201913748QA (cg-RX-API-DMAC7.html)
WO (1) WO2017026331A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240149974A (ko) * 2015-08-11 2024-10-15 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 항체
WO2018175453A1 (en) * 2017-03-20 2018-09-27 City Of Hope Cs1 targeted chimeric antigen receptor-modified t cells for treatment of al amyloidosis
CN110577605A (zh) * 2018-06-11 2019-12-17 浙江启新生物技术有限公司 一种靶向多发性骨髓瘤多种抗原的嵌合抗原受体t(car-t)细胞的构建方法及其应用
WO2023013765A1 (ja) * 2021-08-06 2023-02-09 大塚製薬株式会社 キメラ抗原受容体を検出するためのプライマーセット
WO2023022235A1 (ja) 2021-08-20 2023-02-23 大塚製薬株式会社 組み合わせ医薬
EP4720125A1 (en) 2023-05-30 2026-04-08 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
EP4762093A1 (en) 2023-08-14 2026-06-24 Paragon Therapeutics, Inc. Alpha 4 beta 7 integrin binding proteins and methods of use

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3180125B2 (ja) 1992-03-07 2001-06-25 道生 河野 ヒト成熟骨髄腫細胞に対するモノクローナル抗体
JPH06303990A (ja) * 1993-04-24 1994-11-01 Kanebo Ltd モノクローナル抗体、それを産生するハイブリドーマおよび該抗体の製造方法
EP0833910A1 (en) 1996-04-15 1998-04-08 Icos Corporation Cytoplasmic modulators of integrin regulation/signaling
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US6376654B1 (en) 1999-08-13 2002-04-23 Molecular Discoveries, Llc Myeloma cell and ovarian cancer cell surface glycoproteins, antibodies thereto, and uses thereof
HUE033129T2 (en) * 2003-07-24 2017-11-28 Innate Pharma Sa Methods and compositions for increasing the efficacy of therapeutic antibodies using compounds that potentiate NK cells
AU2003286499A1 (en) * 2003-10-17 2004-06-06 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Interference with c-maf function in multiple myeloma
SMP200800064B (it) 2006-04-21 2009-11-06 Novartis Ag Composizioni farmaceutiche di anticorpi anti-cd40 antagonista
EP2315779A2 (en) 2008-07-09 2011-05-04 Biogen Idec MA Inc. Compositions comprising antibodies to lingo or fragments thereof
PE20120497A1 (es) 2009-03-20 2012-05-14 Amgen Inc Anticuerpo antagonista especifico para el heterodimero de alfa-4-beta-7
US9097717B2 (en) 2009-04-10 2015-08-04 Osaka University Methods of killing myeloma stem and precursor cells by administering anti-CD48 antibodies
WO2012022634A1 (en) * 2010-08-16 2012-02-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) Classification, diagnosis and prognosis of multiple myeloma
UA116189C2 (uk) * 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
EP2814846B1 (en) 2012-02-13 2020-01-08 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
CN103374073A (zh) 2012-04-26 2013-10-30 中国科学院上海生命科学研究院 识别活化形式整合素α4β7的人源化单克隆抗体
JP6615745B2 (ja) * 2013-03-27 2019-12-04 ジェネンテック, インコーポレイテッド ベータ7インテグリンアンタゴニストによる胃腸炎症障害の治療を評価するためのバイオマーカーの使用
JP6693872B2 (ja) * 2013-07-25 2020-05-13 シトムクス セラピューティクス,インコーポレイティド 多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法
KR20240149974A (ko) * 2015-08-11 2024-10-15 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 항체

Similar Documents

Publication Publication Date Title
JP2023171775A5 (cg-RX-API-DMAC7.html)
JP2022184985A5 (cg-RX-API-DMAC7.html)
JP2023166402A5 (cg-RX-API-DMAC7.html)
JP2023103258A5 (cg-RX-API-DMAC7.html)
JP2021184963A5 (cg-RX-API-DMAC7.html)
JP2023145572A5 (cg-RX-API-DMAC7.html)
JP2024116190A5 (cg-RX-API-DMAC7.html)
JP2025511899A5 (cg-RX-API-DMAC7.html)
JP2023518821A5 (cg-RX-API-DMAC7.html)
JP2022541332A5 (cg-RX-API-DMAC7.html)
JP2025176106A5 (cg-RX-API-DMAC7.html)
JP2022543046A5 (cg-RX-API-DMAC7.html)
JP2022068302A5 (cg-RX-API-DMAC7.html)
JP2023514727A5 (cg-RX-API-DMAC7.html)
JP2023181322A5 (cg-RX-API-DMAC7.html)
JP2022538797A5 (cg-RX-API-DMAC7.html)
JP2023552816A5 (cg-RX-API-DMAC7.html)
JP2023022224A5 (cg-RX-API-DMAC7.html)
JP2024045126A5 (cg-RX-API-DMAC7.html)
JP2023100857A5 (cg-RX-API-DMAC7.html)
JP2025098156A5 (cg-RX-API-DMAC7.html)
JP2023078173A5 (cg-RX-API-DMAC7.html)
JP2024149687A5 (cg-RX-API-DMAC7.html)
JP2024099585A5 (cg-RX-API-DMAC7.html)
JP2025094038A5 (cg-RX-API-DMAC7.html)